AOTMiT: What will the Transparency Council address in August?

TRANSPARENCY COUNCIL MEETING NO. 31/2023 AUGUST 7, 2023

1. darzalex (daratumumabum) - CONDITIONAL Indication: under drug program B.54. "Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)". Decision-making problem: preparation of a position paper on the evaluation of the drug

2. Orgovyx (Relugolixum) CONDITIONAL Indication: advanced hormone-dependent prostate cancer Decision problem: preparing a position paper on the evaluation of the drug

3. Strensiq (asfotasum alfa) CONDITIONAL Indication: under the drug program "Treatment of bone symptoms in the course of pediatric hypophosphatasia (HPP) (ICD-10 E83.3) with asfotasum alfa" Decision problem: preparation of a position paper on the evaluation of the drug

4. "Program of rehabilitation and support of physical activity of residents in the Municipality of Gogolin for 2024- 2027",

"Program for early detection of hearing and vision defects in children in the Municipality of Gogolin for 2024-2027",

"Program for the prevention of overweight and obesity in children and adolescents in the Municipality of Gogolin for 2024-2027",

"Pneumococcal infection prevention program for residents of Stalowa Wola aged 60+",

"Infertility treatment by in vitro fertilization - in vitro for residents of Kotla Municipality in 2023-2027",

"Healthier Kolobrzeg - rehabilitation for seniors" Decision-making problem: preparing opinions on draft health policy programs of local government units

TRANSPARENCY COUNCIL MEETING NO. 32/2023 AUGUST 14, 2023

1. adcetris (brentuximabum vedotinum) CONDITIONAL INDICATION: under the drug program "Treatment of patients with classical hodgkin's lymphoma (ICD-10: C81)". Decision-making problem: preparation of a position paper on the evaluation of the drug

2. kyprolis (carfilzomibum) CONDITIONAL Indication: under the drug program "Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)". Decision-making problem: preparing a position paper on the evaluation of the drug

3. Entresto (sacubitrilum + valsartanum) - CONDITION Indication: in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction 2 Decision problem: preparing a position paper on the evaluation of the drug

4. Forsteo (teriparatidum) Indication: hypoparathyroidism Decision-making problem: preparation of a position on the appropriateness of granting reimbursement approval for a medicinal product

5. "Health policy program for residents of the Municipality of Slawno in the field of therapeutic rehabilitation for 2023-2027", "Program for prevention of pneumococcal infections for people aged 65 and older from the municipality of Sandomierz", "Program for prevention of depressive disorders among children and adolescents aged 12-18 attending schools in the municipality of Pawlowice for 2023-2027" Decision-making problem: preparation of opinions on draft health policy programs of local government units

TRANSPARENCY COUNCIL MEETING NO. 33/2023 AUGUST 21, 2023

1. tysabri (natalizumab) CONDITIONAL Indication: under drug program B.29. "Treatment of patients with multiple sclerosis (ICD-10: G35)" Decision-making problem: preparing a position paper on the evaluation of the drug

2. rxulti (brexpiprazole) - CONDITIONAL Indication: for the treatment of schizophrenia in adult patients after ineffectiveness or poor tolerance, or in case of contraindications to therapy with other second-generation antipsychotics Decision problem: preparing a position paper on the evaluation of the drug

3. "Program of rehabilitation of seniors - residents of the municipality of Swieciechowa for 2023-2027", "Program of prevention of type 2 diabetes for residents of the municipality of Olecko aged 40-65 years for 2024- 2026", "Improvement of quality of health and comfort of life of residents of Kamieniec Ząbkowicki for 2024- 2025". Decision-making problem: preparation of opinions on draft health policy programs of local government units

TRANSPARENCY COUNCIL MEETING NO. 34/2023 AUGUST 28, 2023

1. to prepare an opinion on the merits of modifying the conditions for the implementation of guaranteed services at the level of outpatient specialized care, in terms of: 1) expansion of the population to adults - over 26 years of age for the provision of: "Treatment of diabetes with insulin with an insulin pump: insertion of an insulin pump" (currently funded in type 1 diabetes up to 26 years of age), 2) introduction of advice covering qualification of the patient for implementation of the Continuous Glycemic Monitoring System in real time (CGM-RT) or its continuation, including insertion of the sensor and initialization of the system - in patients with type 1 or 3 diabetes treated with an insulin pump CONDITIONAL 3 Indication: insulin-dependent diabetes mellitus, type 1 diabetes Problem for decision-making: preparation of an opinion

2. Lamzede (velmanase alfa) Indication: alpha-mannosidosis in a patient continuing treatment in which he or she has benefited Decision problem: preparation of a position paper on the appropriateness of granting reimbursement approval for the medicinal product.

Source: AOTMiT